药明生物授权欧洲公司Almirall使用全球创新平台WuXiBody™开发多个皮肤病治疗双抗

中国上海和西班牙巴塞罗那

2020年1月9日

全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics，2269.HK）与专注皮肤健康的国际化制药公司Almirall共同宣布，双方针对多个用于治疗皮肤病的创新双特异性抗体签署战略合作协议。

根据协议条款，Almirall公司获得授权使用药明生物具有自主知识产权的多个抗体技术平台，包括满足不同生物学特性需求、具有独特灵活性的WuXiBody™双特异性抗体技术平台，以发现多个创新双特异性抗体。药明生物将获得平台授权首付款，产品开发、批准注册和商业化里程碑付款，以及产品上市后按全球销售额计算的销售提成。

WuXiBody™是药明生物具有自主知识产权的双特异性抗体技术平台。该平台突破了绝大多数双特异性抗体平台技术瓶颈，有效克服了双特异性抗体开发过程中表达量低、多聚体高、纯化收率低等挑战，具有为每个项目节约6到18个月研发时间以及显著降低双特异性抗体生产成本等优势。

WuXiBody™平台几乎可将所有抗体序列用以构建双特异性抗体，并且有望降低免疫原性风险及延长其体内半衰期。WuXiBody™平台还兼具独特的灵活性，可以构建各种不同的价数（如二价、三价或四价双特异性抗体），以满足不同项目的生物学特性需求。

Almirall是一家专注皮肤健康的国际化制药公司，致力于与医疗健康专家合作，应用科学为患者及后代提供医疗解决方案。公司专注于对抗皮肤疾病，帮助人们感受和展现自己的最佳状态。公司为医疗健康专家提供长期支持，不断实现医疗解决方案的创新突破，满足各种专业领域需求。

Almirall公司成立于1943年，总部位于西班牙巴塞罗那，已在西班牙证券交易所上市（股票代码：ALM）。公司坚守对主要股东的承诺，积极应对疾病挑战，提供疾病解决方案，努力创造社会价值。公司2018年总收益达8.11亿欧元，目前拥有超过1800名科研人员。如需更多信息，请访问：www.almirall.es。

药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。截至2019年6月30日，在药明生物平台上研发的综合项目达224个，包括106个处于临床前研究阶段，102个在临床早期（I期，II期）阶段，15个在后期临床（III期）以及1个在商业化生产阶段。预计到2022年，公司在中国、爱尔兰、新加坡、美国规划的生物制药生产基地合计产能将超过28万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。如需更多信息，请访问：www.wuxibiologics.com.cn。

SHANGHAI, China and BARCELONA, Spain

January 9, 2020

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Almirall, a leading skin-health focused global pharmaceutical company, today announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.

Under the terms of the agreement, Almirall gains access to WuXi Biologics’ proprietary antibody platforms including WuXiBody™, a versatile bispecific platform with flexible valency to fit target biology, to discover multiple novel bispecific antibodies. WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments for each bispecific antibody generated from this platform, and will also be entitled to royalties based on global sales generated by these projects.

WuXiBody™ is a leading proprietary bispecific antibody platform developed by WuXi Biologics. It can effectively break through the CMC barriers for many bispecific antibodies development with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing cost, a limitation still facing by many other current bispecific platforms.

WuXiBody™ Platform enables almost any mAb sequence pairs to be assembled into bispecific constructs. They are expected to have low immunogenicity risk and longer in vivo half-life. WuXiBody™ Platform also has its unique structural flexibility, which makes it convenient to build various formats with different combination of valencies (1+1, 1+2, 2+2) to meet the requirements of different target biology.

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded almost 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others by understanding their challenges and using science to provide solutions for real life. Total revenues in 2018 were 811 million euros. Almirall has more than 1,800 employees dedicated to research. For more information see www.almirall.es.

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects,including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.